Oral ponesimod for psoriasis compared to other investigational therapies

Abstract

Oral ponesimod is a new therapy for the treatment of moderate-to-severe plaque psoriasis. Vaclavkova et al conducted a phase 2 trial that demonstrated moderate efficacy of ponesimod in the treatment of psoriasis. Here we discuss various biologic agents with alternative mechanisms of action, that have demonstrated superior efficacy in psoriasis, and call into question the risks versus benefits of ponesimod therapy.